FLT3 ITD and TKD Mutation Detection
Also known as: FLT3-PCR
Use
This test aids in the diagnosis and management of acute myeloid leukemia (AML). FLT3 mutations occur in 20-30% of cytogenetically normal AML cases, representing an important diagnostic and prognostic marker. The test is designed to detect both internal tandem duplication (ITD) and D835 tyrosine kinase domain (TKD) mutations, essential for diagnosis and therapy decisions in AML.
Special Instructions
The test is not intended for minimal residual disease monitoring. Patients should have blood or bone marrow collected in EDTA (lavender) or sodium heparin (green) tubes. Proper handling of specimens and timely transport is critical to ensure test accuracy.
Limitations
The FLT3 ITD and TKD Mutation Detection test only identifies the ITD and D835 mutations and does not detect other FLT3 mutations. It requires a minimum signal ratio of 0.05 for detection. Results should be considered alongside clinical context and other relevant data. Negative results do not rule out low-level mutations or rare FLT3 mutations that the test isn't designed to detect.
New York Approved
Methodology
PCR-based
Biomarkers
LOINC Codes
- 31208-2
- 79210-1
- 92844-0
- 69548-6
- 50398-7
Result Turnaround Time
2-7 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
5 mL
Minimum Volume
1 mL
Container
Lavender (EDTA) or Green (sodium heparin) tube
Collection Instructions
Do not freeze.
Storage Instructions
Refrigerated.
Causes for Rejection
Plasma, serum, FFPE tissue blocks/slides, or frozen tissue, specimens collected in anticoagulants other than EDTA, clotted or grossly hemolyzed specimens.
Stability Requirements
| Temperature | Period |
|---|---|
| Refrigerated | 7 days |
| Frozen | Unacceptable |